Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Becker, JC; Andersen, MH; Hofmeister-Muller, V; Wobser, M; Frey, L; Sandig, C; Walter, S; Singh-Jasuja, H; Kampgen, E; Opitz, A; Zapatka, M; Brocker, EB; Straten, PT; Schrama, D; Ugurel, S; .
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Cancer Immunol Immunother. 2012; 61(11):2091-2103 Doi: 10.1007/s00262-012-1266-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Becker Jürgen Christian
Co-authors Med Uni Graz: Schrama David; Ugurel-Becker Selma
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets. Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic inhibitor-of-apoptosis protein crucial for the survival of tumor cells, in HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma. The study endpoints were survivin-specific T-cell reactivity (SSTR), safety, response, and survival (OS). Results Sixty-one patients (ITT) received vaccination therapy using three different regimens. 55 patients (PP) were evaluable for response and survival, and 41/55 for SSTR. Patients achieving progression arrest (CR + PR + SD) more often showed SSTRs than patients with disease progression (p = 0.0008). Patients presenting SSTRs revealed a prolonged OS (median 19.6 vs. 8.6 months; p = 0.0077); multivariate analysis demonstrated SSTR as an independent predictor of survival (p = 0.013). The induction of SSTRs was associated with gender (female vs. male; p = 0.014) and disease stage (M1a/b vs. M1c; p = 0.010), but not with patient age, HLA type, performance status, or vaccination regimen. Conclusion Survivin-specific T-cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin-derived peptides is a promising treatment strategy in melanoma.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Cancer Vaccines - immunology; Female -; HLA-A1 Antigen - immunology; HLA-A2 Antigen - immunology; HLA-B35 Antigen - immunology; Humans -; Inhibitor of Apoptosis Proteins - immunology; Male -; Melanoma - immunology; Middle Aged -; Neoplasm Staging -; Peptides - immunology; Sex Factors -; Skin Neoplasms - immunology; T-Lymphocytes - immunology; Treatment Outcome -; Vaccines, Subunit - therapeutic use
Find related publications in this database (Keywords): Melanoma; Survivin; T-cell reactivity; Therapy; Peptide vaccination